ResearcherUPMC Hillman Cancer CenterNo recent work listed

Kimmen Quan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8677-6026; OpenAlex author ID A5110537572. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 6

Papers, trials and grants by year

2018: 1 paper

Papers 1

Results of a prospective phase 2 clinical trial of induction gemcitabine/capecitabine followed by stereotactic ablative radiation therapy in borderline resecta… Co-author DOI 10.1016/j.prro.2017.10.001 ↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Steven A. Burton · 1 shared paper, 2018 · strength 0.08
- Paper Results of a prospective phase 2 clinical trial of induction gemcitabine/capecitabine followed by stereotactic ablative… DOI 10.1016/j.prro.2017.10.001 ↗
Dwight Earl Heron · 1 shared paper, 2018 · strength 0.08
- Paper Results of a prospective phase 2 clinical trial of induction gemcitabine/capecitabine followed by stereotactic ablative… DOI 10.1016/j.prro.2017.10.001 ↗
Philip Anthony Sutera · 1 shared paper, 2018 · strength 0.08
- Paper Results of a prospective phase 2 clinical trial of induction gemcitabine/capecitabine followed by stereotactic ablative… DOI 10.1016/j.prro.2017.10.001 ↗
Rodney E. Wegner · 1 shared paper, 2018 · strength 0.08
- Paper Results of a prospective phase 2 clinical trial of induction gemcitabine/capecitabine followed by stereotactic ablative… DOI 10.1016/j.prro.2017.10.001 ↗
Herbert J. Zeh · 1 shared paper, 2018 · strength 0.08
- Paper Results of a prospective phase 2 clinical trial of induction gemcitabine/capecitabine followed by stereotactic ablative… DOI 10.1016/j.prro.2017.10.001 ↗
Nathan Bahary · 1 shared paper, 2018 · strength 0.08
- Paper Results of a prospective phase 2 clinical trial of induction gemcitabine/capecitabine followed by stereotactic ablative… DOI 10.1016/j.prro.2017.10.001 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.